Clinical Trials
115 trialsA Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Northwestern University
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Faeth Therapeutics
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
ResQ108B-PANC
ImmunityBio, Inc.
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
City of Hope Medical Center
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
Testing the Addition of the Anti-cancer Viral Therapy Telomelysinâ„¢ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
The Seven Trial: Exploiting the Unfolded Protein Response
HonorHealth Research Institute
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
City of Hope Medical Center
MK-4830-001
Merck Sharp & Dohme LLC
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
ProDa BioTech, LLC
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
MK-0482-001
Merck Sharp & Dohme LLC
KETO-CARE
Ohio State University Comprehensive Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
IntenSify
German Cancer Research Center
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Nab-PIPAC
University Hospital, Geneva
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Vanderbilt-Ingram Cancer Center
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
ProglumidePanc
Georgetown University
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
National Cancer Institute (NCI)